Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer's disease
Por:
Jacobs, T, Brien, CO, Figueredo, L, Gogola, A, Gaggi, NL, Hurwitz, B, Pirraglia, E, Herzog, S, Ramos-Cejudo, J, Shepherd, TM, Palta, P, Fortea, J, Wisniewski, TM, Betensky, RA, Lopresti, B, Mielke, MM, Convit, A, Osorio, RS
Publicada:
11 oct 2025
Resumen:
INTRODUCTION Blood-based biomarkers (BBMs) are promising tools for Alzheimer's disease (AD) diagnosis, but their accuracy may be affected by body mass index (BMI) and blood volume (BV) through dilution. We investigated how BMI and BV influence BBM concentrations and PET prediction. METHODS Data from 241 cognitively unimpaired participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) were examined to evaluate the influence of BMI/BV on BBMs (A beta 42/40, p-Tau181, p-Tau217, glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL]) and BBM-based PET predictions. RESULTS Elevated BMI/BV associated with lower BBM concentrations, especially for p-Tau217 and NfL, independent of brain amyloid burden. BMI-stratified thresholds improved amyloid PET prediction, with higher BBM thresholds and area under the curve (AUC) values seen in normal weight compared to overweight or obese participants. Drastic BMI/BV declines due to weight loss increased BBM variability and systematic PET misclassification. DISCUSSION Adjusting for BMI/BV in BBM-based diagnostics appears to improve accuracy and reliable detection of AD pathology, especially in preclinical stages.
Filiaciones:
Jacobs, T:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Penn State Coll Med, Hershey, PA USA
Brien, CO:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Figueredo, L:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Gogola, A:
Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA
Gaggi, NL:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Hurwitz, B:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Pirraglia, E:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Herzog, S:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
Ramos-Cejudo, J:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
VA Boston Healthcare Syst, VA Boston Cooperat Studies Program, MAVERIC, Boston, MA USA
Shepherd, TM:
NYU, Grossman Sch Med, Dept Radiol, New York, NY USA
Palta, P:
Univ North Carolina, Dept Neurol, Chapel Hill, NC USA
Fortea, J:
Univ Autonoma Barcelona, Hosp St Pau, Inst Invest Biomed St Pau, Dept Neurol,St Pau Memory Unit, Barcelona, Spain
Fundacio Catalana Sindrome, Barcelona Med Ctr, Barcelona, Spain
Inst Salud Carlos III CIBER ISCIII, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Wisniewski, TM:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
NYU, Ctr Cognit Neurol, Grossman Sch Med, Dept Neurol, New York, NY USA
NYU, Grossman Sch Med, Dept Pathol, New York, NY USA
Betensky, RA:
NYU, Sch Global Publ Hlth, Dept Biostat, 708 Broadway, Broadway, NY USA
Lopresti, B:
Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA
Mielke, MM:
Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA
Convit, A:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
NYU, Grossman Sch Med, Dept Radiol, New York, NY USA
Osorio, RS:
NYU, Grossman Sch Med, Dept Psychiat, New York, NY USA
NYU, Ctr Cognit Neurol, Grossman Sch Med, Dept Neurol, New York, NY USA
Nathan S Kline Inst Psychiat Res, Orangeburg, NY USA
Green Submitted, hybrid
|